Get started
fredtahmasian

Nightstar Therapeutics

fredtahmasian  
NASDAQ:NITE   None
Beyond Technical Analysis
2
1
beyondta
11/20/2017
800M market cap. 23 employees. UK.
69M in cash. Burning $10M/yr
a gene therapy for the treatment of CHM. We expect to begin Phase 3 clinical development of NSR-REP1 in the first half of 2018. Phase II data due?
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.